Bruton's tyrosine kinase inhibitors

A compound of Formula (I) or (II) having the following structure, an isomer thereof, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof:

• wherein:
• A, B, G, and D are each independently N or CR', with the proviso that only one or two of A, B, G, and D can be N;
• R1 is hydrogen, alkyl, —OR1A, amino, —OH, —CN, —NHOH, —NR1AR1B or —CONH2;
• R2 is independently hydrogen, halogen, —CZ3, —CHZ2, —CH2Z, —OCZ3—OCH2Z, —OCHZ2, —CN, —SOnNR2AR2B, —NHC(O)NR2AR2B, —N(O)n, —NR2AR2B, —C(O)R2A, —C(O)—OR2A, —C(O)NR2AR2B, —SOnR2A, —OR2A, —NR2CSO2R2B, —NR2CC(O)R2A, —NR2CC(O)OR2A, —NR2AOR2B, substituted or unsubstituted alkyl, optionally substituted with one to five fluorines substituted or unsubstituted heteroalkyl, optionally substituted with one to five fluorines substituted or unsubstituted cycloalkyl, optionally substituted with one to five fluorines;
• substituted or unsubstituted heterocycloalkyl, optionally substituted with one to five fluorines, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein two adjacent R2 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, and y is an integer from 0 to 5;
• M is substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-10 cycloalkyl, substituted or unsubstituted C3-10 cycloalkenyl, substituted or unsubstituted 3 to 10 membered heterocycloalkyl, substituted or unsubstituted 3 to 10 membered heterocycloalkenyl and 5 to 10 membered heteroaryl, wherein, when substituted, M contains from 1 to 9 substituents independently selected at each occurrence from the group consisting of halo, —OR2A, —NR2AR2B, ═O, —CN, —C(O)OR2A, —OC(O)R2A, —C(O)NR2AR2B, —NR2CC(O)R2A, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl substituted with —OR2A, optionally substituted with one to five fluorines C3-8 cycloalkyl, —SO2R2A, SO3R2A, C(O)R2A and a 3 to 8 membered heterocyclic group;
• -X-E is one of the followings:
• (1) X is O, —OCR2AR2B—, —CR2AR2BO—, —S(O)—, —S(O)2—, S(O)2—, —CR2AR2B—, —CR2AR2BNR2C(C═O) CR2AR2B(C═O)NR2C—, —(C═O)NR2CCR2AR2B—, —NR2C(C═O)CR2AR2B—, or a bond;
• and E is a hydrogen, an aryl or a heteroaryl substituted with one to five R3 substituents;
• or a 3-7 membered saturated or partially unsaturated carbocyclic ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• or (2) -X-E is hydrogen, halogen, —OR2A, —O(CH2)1-4R2A, —CN, —NO2;
• R1a, R1B, R2A, R2B and R2C are each independently hydrogen, —CZ3, —CN, —COOH, —CONH2, —CHZ2, —CH2Z, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl, and R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
• Z is independently —F, —Cl, —Br or —I;
• and
• n is independently an integer from 1 to 2.